Search results | regenerative

Reports

Regenerative Medicine Partnering Terms and Agreements

The Regenerative Medicine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.

Insights

Regenerative Medicine deal trends article

The field of regenerative medicine is an up and coming new approach of targeting and treating diseases, it involves the repair and restoration of previously damaged tissues or organs in the body. The regenerative medicine market was worth $16bn in 2013 and industry analysts predict that this will leap to over $60bn by 2020. The more »

Regenerative medicine: recent partnering deal trends

Regenerative medicine has become increasingly popular in recent years, with the number of deals announced growing steadily

Regenerative medicine

Regenerative medicine is the process of replacing or regenerating human cells, tissues or organs to…

Baxter

Baxter is a top pharmaceutical company based in Deerfield, Illinois, USA

Stem cells

Stem cells are cells found in all multicellular organisms, that can divide and differentiate into diverse specialized…

Dermatology

Dermatology is the collective term used to describe the study of diseases that affect the skin, hair and nails.

Current Agreements Deal analysis Update : September 2013

This month we are providing you with an overview of deal analysis in the life sciences, covering partnering and M&A in August 2013

Partnering with Baxter: A leader in healthcare

Baxter is a top pharmaceutical company active in partnering, licensing and M&A in medical devices, pharmaceuticals and biotechnology

Partnering with Shire: Search and Development

Shire is a top pharma company active in partnering, licensing and M&A in biopharmaceuticals

Baxter: Company Profile

Baxter is a global healthcare company with expertise in medical devices, pharmaceuticals and biotechnology

Events

Development agreement for human regenerative therapy with induced pluripotent stem cells

Catalent Pharma Solutions announced an agreement with the Center for iPS Cell Research and Application at Kyoto University in Japan to make a major advancement toward one of the first regenerative human therapies with induced pluripotent stem (iPS) cells applicable to humans.

Deals

Collaboration agreement for researching regenerative medicine

NUI Galway and the Mayo Clinic in the US plan to collaborate on clinical trials using regenerative medicine, following the signing of a memorandum of understanding between the two institutes.

Joint venture agreement for regenerative medicine

Bioheart has entered into a joint venture with Magnum Cell Therapies.

Development agreement for human regenerative therapy with induced pluripotent stem cells

Catalent Pharma Solutions announced an agreement with the Center for iPS Cell Research and Application at Kyoto University in Japan to make a major advancement toward one of the first regenerative human therapies with induced pluripotent stem (iPS) cells applicable to humans.

Cytomedix expands commitment to regenerative medicine with acquisition of Aldagen

Cytomedix announces the completion of the acquisition of Aldagen. Under the terms of the transaction as described below, Cytomedix issued preferred shares valued at $16 million based on a 10-day volume-weighted average price (“VWAP”) calculated through February 2, 2012.

Cephalon, Inc. and Mesoblast Limited enter into strategic alliance to develop and commercialise novel therapeutic products for regenerative medicine

Cephalon, Inc. and Mesoblast Limited have announced they have entered into a strategic alliance to develop and commercialise novel adult Mesenchymal Precursor Stem Cell (MPC) therapeutics for degenerative conditions of the cardiovascular and central nervous systems.

AstraZeneca establishes four CRISPR technology pacts

AstraZeneca announces collaborations to use CRISPR technology for genome editing across its drug discovery platform

Histogenics files for $65 million in IPO financing

Histogenics filed with the SEC to raise up to $65 million in an initial public offering financing.

Joint venture agreement for Biologistex CCM

BioLife Solutions announced the formation of a joint venture under the brand name of biologistex Cold Chain Management.

Asset purchase agreement for stem cell reagent and services business unit

Stemgent has completed the sale of its stem cell reagents and services business to ReproCELL in a cash transaction for approximately $8.5 million.

Aastrom has signed a biotech deal with Sanofi

Aastrom Biosciences has entered into a definitive biotech deal agreement to acquire Sanofi‘s Cell Therapy and Regenerative Medicine business for a purchase price of $6.5 million.